An expert underscores the importance of early expectation setting around chronicity, symptom variability, and realistic treatment goals for children with functional constipation or IBS-C.
Julie Khlevner, MD, AGAF
Advertisement
Julie Khlevner, MD, AGAF, is Associate Professor of Pediatrics at Columbia University Medical Center and Chair, NASPGHAN Neurogastroenterology and Motility Committee.
Articles by Julie Khlevner, MD, AGAF
Learn how Rome V criteria, predominant symptom drivers, and a positive diagnostic framework help clinicians distinguish functional constipation from pediatric IBS-C and move away from a diagnosis-of-exclusion mindset.
Julie Khlevner, MD, discusses the clinical impact of FDA approval of linaclotide for children aged 2 to 5 years with functional constipation.
Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C
Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Recent advances in the treatment of molluscum contagiosum
2
FDA grants priority review to Tivicay PD for neonatal HIV
3
FDA approves first generic rifapentine for tuberculosis treatment, prevention in 12 years and older
4
RSV Monoclonal Antibody Resistance: What Clinicians Need to Know
5